BioSpace News Archive

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company) today highlighted an analysis of eleven unblinded participants from the 201 Trial evaluating risvodetinib (IkT-148009) in untreated Parkinson’s disease.

Olema Pharmaceuticals, Inc. today announced an oral presentation on the Phase 2 monotherapy study results of palazestrant (OP-1250), the Company’s complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) for the treatment of metastatic breast cancer, at the upcoming European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, on October 22, 2023.

Bio-Techne Corporatio announced that its Wallingford, CT facility has received ISO 13485:2023 certification for its quality management system, demonstrating the company’s commitment to producing products for clinical applications.

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of two abstracts for posters to be presented during the upcoming European Society for Medical Oncology (ESMO) Congress 2023, taking place from October 20th to 24th at the IFEMA Madrid Conference Center in Madrid, Spain.

Biohaven Ltd. (NYSE: BHVN) (“Biohaven”), announced the presentation of preclinical data demonstrating the ability of taldefgrobep alfa to significantly reduce fat mass while increasing lean mass in an obese mouse model.

Ginkgo Bioworks and Zenfold Sustainable Technologies announced a collaboration to leverage Ginkgo Enzyme Services in its effort to discover an enzyme critical to the manufacturing of veterinary products.

AstraZeneca’s supplemental New Drug Application (sNDA) for TAGRISSO® (osimertinib) in combination with chemotherapy has been accepted and granted Priority Review in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).

Exscientia plc (Nasdaq: EXAI) today announced two abstracts to be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2023 from October 20-24, 2023 in Madrid, Spain.

Summit Therapeutics Inc. announced that Manmeet S. Soni has been appointed as the Company’s Chief Operating Officer, effective immediately.

Xeris Biopharma Holdings, Inc. announced that, it is raising its full-year 2023 financial guidance and that it has received a $6 million milestone payment from Amgen, which acquired Horizon Therapeutics, for developing an ultra-concentrated, ready-to-use, subcutaneous injection of TEPEZZA® that met the target product profile set forth in the research collaboration and option agreement signed in November 2022.